3/15/2024 0 Comments Lung crackles sound![]() These medicines were later permitted at the discretion of the investigator, following 6 months of study treatment.īecause patients with IPF had already been studied, specific efforts were made to enroll patients with a chronic progressive fibrotic phenotype other than IPF These short, explosive or popping sounds are heard primarily through the chest wall with a stethoscope, but they may also be heard at the. Patients who were treated with azathioprine, cyclosporine, mycophenolate mofetil, tacrolimus, rituximab, cyclophosphamide, or oral glucocorticoids (at a dose of more than 20 mg per day for glucocorticoids) were excluded. Crackles, formerly known as rales, are discontinuous, intermittent, nonmusical sounds that are described according to their timing and duration within the respiratory phase, intensity, pitch, and location. Enrolled patients had features of fibrotic lung disease affecting more than 10% of lung volume on high-resolution CT. ![]() At the time of enrollment, patients were required to have an FVC of at least 45% of the predicted value and a diffusing capacity of the lung for carbon monoxide (corrected for hemoglobin) of 30 to less than 80% of the predicted value. Patients were required to meet at least one of the following criteria for progression of interstitial lung disease within the 24 months before screening, despite standard treatment with an agent other than nintedanib or pirfenidone: a relative decline in the FVC of at least 10% of the predicted value, a relative decline in the FVC of 5% to less than 10% of the predicted value and worsening of respiratory symptoms or an increased extent of fibrosis on high-resolution CT, or worsening of respiratory symptoms and an increased extent of fibrosis. FVC was 50% or more of the predicted value, diffusion capacity of the lung for carbon monoxide (DLCO) was 30 to 79% of the predicted value, and high-resolution computed tomography (HRCT) of the chest performed within the previous 12 monthsĬoncomitant therapy with up to 15 mg of prednisolone per day, or the equivalent, was permitted if the dose had been stable for 8 or more weeks before screening patients receiving other therapies for idiopathic pulmonary fibrosis, including high-dose prednisolone, azathioprine, N-acetylcysteine, and any investigational treatments for idiopathic pulmonary fibrosis, were excluded Patients were 40 years of age or older and had received a diagnosis of idiopathic pulmonary fibrosis within the previous 5 years. Time to the first acute exacerbation change from baseline in the total score on the St. Key secondary end-points (measured at week 52) ![]() OFEV® 150 mg twice daily (n=638) or placebo (n=423)Īnnual rate of decline in the forced vital capacity (FVC), as assessed over a 52-week period Patients diagnosed with idiopathic pulmonary fibrosis (IPF) within the previous 5 years Two replicate 52-week, randomised, double-blind, phase 3 trials (INPULSIS®-1 and INPULSIS®-2) at 205 sites in 24 countries
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |